SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...

The in-vivo biological activity of a drug is contingent on its ability to get to the intended site of action, commonly through a transport process that involves barrier penetration and crossing yet is ...

Advanced Strategies to Study Plasma Protein Binding, Improve PK/PD, and Develop Better Enzyme Inhibitors In early drug discovery, the molecular hits generated from a high throughput screen (HTS) are ...

Due to the escalating downstream costs in the development phase, objective quality assessment of lead series long before entering clinical trials is an increasing necessity within pharmaceutical ...